JP5409015B2 - ヒストンデアセチラーゼ阻害剤 - Google Patents

ヒストンデアセチラーゼ阻害剤 Download PDF

Info

Publication number
JP5409015B2
JP5409015B2 JP2008555472A JP2008555472A JP5409015B2 JP 5409015 B2 JP5409015 B2 JP 5409015B2 JP 2008555472 A JP2008555472 A JP 2008555472A JP 2008555472 A JP2008555472 A JP 2008555472A JP 5409015 B2 JP5409015 B2 JP 5409015B2
Authority
JP
Japan
Prior art keywords
moiety
substituted
compound
certain embodiments
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008555472A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009526865A (ja
JP2009526865A5 (enExample
Inventor
ステュワート エル． シュライバー，
ジェームス エリオット ブラドナー，
ラルフ マジッツチェック，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of JP2009526865A publication Critical patent/JP2009526865A/ja
Publication of JP2009526865A5 publication Critical patent/JP2009526865A5/ja
Application granted granted Critical
Publication of JP5409015B2 publication Critical patent/JP5409015B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
JP2008555472A 2006-02-14 2007-02-14 ヒストンデアセチラーゼ阻害剤 Active JP5409015B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77317206P 2006-02-14 2006-02-14
US60/773,172 2006-02-14
PCT/US2007/062152 WO2007095584A2 (en) 2006-02-14 2007-02-14 Histone Deacetylase Inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013008195A Division JP2013100327A (ja) 2006-02-14 2013-01-21 ヒストンデアセチラーゼ阻害剤

Publications (3)

Publication Number Publication Date
JP2009526865A JP2009526865A (ja) 2009-07-23
JP2009526865A5 JP2009526865A5 (enExample) 2011-09-15
JP5409015B2 true JP5409015B2 (ja) 2014-02-05

Family

ID=38372243

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008555472A Active JP5409015B2 (ja) 2006-02-14 2007-02-14 ヒストンデアセチラーゼ阻害剤
JP2013008195A Pending JP2013100327A (ja) 2006-02-14 2013-01-21 ヒストンデアセチラーゼ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013008195A Pending JP2013100327A (ja) 2006-02-14 2013-01-21 ヒストンデアセチラーゼ阻害剤

Country Status (13)

Country Link
US (5) US8383855B2 (enExample)
EP (1) EP2010168B1 (enExample)
JP (2) JP5409015B2 (enExample)
CN (2) CN103739515B (enExample)
AU (1) AU2007214458C1 (enExample)
BR (1) BRPI0707826B1 (enExample)
CA (1) CA2642288C (enExample)
DK (1) DK2010168T3 (enExample)
ES (1) ES2481413T3 (enExample)
IL (1) IL193458A (enExample)
MX (1) MX2008010462A (enExample)
PL (1) PL2010168T3 (enExample)
WO (1) WO2007095584A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) * 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
SG171690A1 (en) * 2005-03-22 2011-06-29 Harvard College Treatment of protein degradation disorders
DK2010168T3 (da) 2006-02-14 2014-07-21 Harvard College Histondeacetylase-inhibitore
WO2008091349A1 (en) * 2006-02-14 2008-07-31 The President And Fellows Of Harvard College Bifunctional histone deacetylase inhibitors
WO2007130429A2 (en) * 2006-05-03 2007-11-15 The President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
EP2321264B1 (en) * 2008-07-23 2016-05-04 President and Fellows of Harvard College Deacetylase inhibitors and uses thereof
EP2431031B1 (en) * 2009-05-12 2016-06-08 Amorepacific Corporation Composition for preventing hair loss or for stimulating hair growth
US8716344B2 (en) 2009-08-11 2014-05-06 President And Fellows Of Harvard College Class- and isoform-specific HDAC inhibitors and uses thereof
BR112013008615B1 (pt) 2010-10-13 2021-05-11 Medivir Ab composição farmacêutica
CN104447608B (zh) * 2014-11-10 2017-01-11 华东师范大学 含有噻唑啉酮结构的异羟肟酸类小分子有机化合物及其衍生物、用途及其制备方法
CN104744431A (zh) * 2015-03-06 2015-07-01 芜湖杨燕制药有限公司 一种组蛋白去乙酰化酶抑制剂及其制备方法和用途
US20230190717A1 (en) * 2017-04-10 2023-06-22 City Of Hope P38 gamma inhibitors and method of use thereof
CN108299313B (zh) * 2018-01-16 2020-10-02 长沙霍滋生物科技有限公司 一种化合物及其在药学上的应用
CN111943892B (zh) * 2019-05-17 2022-04-05 上海中泽医药科技有限公司 组蛋白去乙酰化酶亚型抑制剂硫乙酰芳胺类化合物及用途
CN114748463A (zh) * 2022-05-25 2022-07-15 中南大学湘雅医院 Remetinostat在制备治疗银屑病的药物中的应用
CN115364226A (zh) * 2022-09-23 2022-11-22 华中科技大学同济医学院附属同济医院 组蛋白去乙酰化酶hdac3在制备防治支架及内膜剥脱术后血管再狭窄的药物中的应用

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3242252A1 (de) 1982-11-15 1984-05-17 Bayer Ag, 5090 Leverkusen Heterocyclisch substituierte hydroxyalkyl-azolyl-derivate
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
ES2008962A6 (es) 1987-12-17 1989-08-16 Marga Investigacion Proceso para la preparacion de nuevos compuestos de 2-guanidinotiazol
JPH01224381A (ja) 1988-03-04 1989-09-07 Japan Tobacco Inc トリコスタチン酸、トリコスタチンａの新規な合成中間体、及びトリコスタチン酸、トリコスタチンａの製造方法。
DE58900825D1 (de) * 1988-06-13 1992-03-26 Ciba Geigy Ag Ungesaettigte beta-ketoesteracetale und ihre anwendungen.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
EP0502060A4 (en) 1989-11-13 1993-05-05 Affymax Technologies N.V. Spatially-addressable immobilization of anti-ligands on surfaces
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5045538A (en) * 1990-06-28 1991-09-03 The Research Foundation Of State University Of New York Inhibition of wasting and protein degradation of mammalian muscle by tetracyclines
GB9026114D0 (en) * 1990-11-30 1991-01-16 Norsk Hydro As New compounds
DK0562025T3 (da) 1990-12-06 2001-06-18 Affymetrix Inc Forbindelser og deres anvendelse i en binær syntesestrategi
EP0501919A1 (de) * 1991-03-01 1992-09-02 Ciba-Geigy Ag Strahlungsempfindliche Zusammensetzungen auf der Basis von Polyphenolen und Acetalen
US5225173A (en) * 1991-06-12 1993-07-06 Idaho Research Foundation, Inc. Methods and devices for the separation of radioactive rare earth metal isotopes from their alkaline earth metal precursors
USRE38506E1 (en) 1991-10-04 2004-04-20 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5239113A (en) * 1991-10-15 1993-08-24 Monsanto Company Substituted β-amino acid derivatives useful as platelet aggregation inhibitors and intermediates thereof
DE69233087T2 (de) 1991-11-22 2003-12-24 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Verfahren zur Herstellung von Polymerarrays
US5359115A (en) 1992-03-26 1994-10-25 Affymax Technologies, N.V. Methods for the synthesis of phosphonate esters
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
HUT72495A (en) 1992-10-01 1996-05-28 Cold Spring Harbor Lab Complex combinatorial chemical libraries encoded with tags
US5480971A (en) 1993-06-17 1996-01-02 Houghten Pharmaceuticals, Inc. Peralkylated oligopeptide mixtures
US5440016A (en) 1993-06-18 1995-08-08 Torrey Pines Institute For Molecular Studies Peptides of the formula (KFmoc) ZZZ and their uses
US20030203976A1 (en) 1993-07-19 2003-10-30 William L. Hunter Anti-angiogenic compositions and methods of use
US5994341A (en) * 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US5362899A (en) 1993-09-09 1994-11-08 Affymax Technologies, N.V. Chiral synthesis of alpha-aminophosponic acids
US5659016A (en) 1994-09-22 1997-08-19 Cancer Institute RPDL protein and DNA encoding the same
US6231600B1 (en) 1995-02-22 2001-05-15 Scimed Life Systems, Inc. Stents with hybrid coating for medical devices
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
JP3330781B2 (ja) 1995-05-22 2002-09-30 三菱エンジニアリングプラスチックス株式会社 ポリカーボネート樹脂組成物
EP0855024A4 (en) 1995-09-20 2001-08-22 Merck & Co Inc HISTONE DEACETYLASE AS THE ATTACK POINT FOR ANTIPROTOZOIC ACTIVE SUBSTANCES
JPH09124918A (ja) 1995-10-30 1997-05-13 Mitsubishi Eng Plast Kk ポリカーボネート樹脂組成物
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US6777217B1 (en) * 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
TW517089B (en) 1996-09-03 2003-01-11 Res Dev Foundation Assessment of intracellular cysteine and glutathione concentrations
US6068987A (en) 1996-09-20 2000-05-30 Merck & Co., Inc. Histone deacetylase as target for antiprotozoal agents
WO1998016830A2 (en) 1996-10-16 1998-04-23 The President And Fellows Of Harvard College Droplet assay system
ZA9710342B (en) * 1996-11-25 1998-06-10 Alza Corp Directional drug delivery stent and method of use.
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
ATE289295T1 (de) 1997-04-22 2005-03-15 Euro Celtique Sa Die verwendung von durch carbozyklische und heterozyklische reste substituierte semicarbazonen und thiosemicarbazonen als natriumkanalblocker
US6190619B1 (en) * 1997-06-11 2001-02-20 Argonaut Technologies, Inc. Systems and methods for parallel synthesis of compounds
US5891507A (en) * 1997-07-28 1999-04-06 Iowa-India Investments Company Limited Process for coating a surface of a metallic stent
US6195612B1 (en) * 1998-01-05 2001-02-27 Tama L. Pack-Harris Pharmacy benefit management system and method of using same
US6428960B1 (en) 1998-03-04 2002-08-06 Onyx Pharmaceuticals, Inc. Selection method for producing recombinant baculovirus
US6306866B1 (en) * 1998-03-06 2001-10-23 American Cyanamid Company Use of aryl-substituted pyrimidines as insecticidal and acaricidal agents
US6153252A (en) * 1998-06-30 2000-11-28 Ethicon, Inc. Process for coating stents
US6248127B1 (en) * 1998-08-21 2001-06-19 Medtronic Ave, Inc. Thromboresistant coated medical device
DE19846008A1 (de) 1998-10-06 2000-04-13 Bayer Ag Phenylessigsäure-heterocyclylamide
CN1330661A (zh) * 1998-12-10 2002-01-09 霍夫曼-拉罗奇有限公司 原胶原c端蛋白酶抑制剂
WO2000036132A1 (en) 1998-12-14 2000-06-22 Merck & Co., Inc. Hiv integrase inhibitors
EP1140916B1 (en) 1998-12-16 2002-11-13 Aventis Pharma Limited Heteroaryl-cyclic acetals
AR035313A1 (es) 1999-01-27 2004-05-12 Wyeth Corp Inhibidores de tace acetilenicos de acido hidroxamico de sulfonamida a base de alfa-aminoacidos, composiciones farmaceuticas y el uso de los mismos para la manufactura de medicamentos.
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
BR0014254A (pt) * 1999-09-08 2002-08-27 Sloan Kettering Inst Cancer Nova classe de agentes de citodiferenciação e inibidores de desacetilase de histona, e métodos de uso dos mesmos
US6203551B1 (en) 1999-10-04 2001-03-20 Advanced Cardiovascular Systems, Inc. Chamber for applying therapeutic substances to an implant device
KR20100035666A (ko) * 1999-11-23 2010-04-05 메틸진 인크. 히스톤 디아세틸라제의 억제제
US6251136B1 (en) * 1999-12-08 2001-06-26 Advanced Cardiovascular Systems, Inc. Method of layering a three-coated stent using pharmacological and polymeric agents
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
GB0023983D0 (en) * 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
CA2423868C (en) * 2000-09-29 2011-06-07 Prolifix Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
US6495719B2 (en) 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
AR035455A1 (es) * 2001-04-23 2004-05-26 Hoffmann La Roche Derivados triciclicos de alquilhidroxamato , procesos para su elaboracion, composiciones farmaceuticas que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos
WO2002089782A2 (en) 2001-05-09 2002-11-14 President And Fellows Of Harvard College Dioxanes and uses thereof
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
US6517889B1 (en) 2001-11-26 2003-02-11 Swaminathan Jayaraman Process for coating a surface of a stent
MXPA04008577A (es) * 2002-03-04 2005-07-13 Aton Pharma Inc Metodos para inducir diferenciacion terminal.
US7148257B2 (en) 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
WO2003101481A1 (en) * 2002-06-03 2003-12-11 Als Therapy Development Foundation Treatment of neurodegenerative diseases using proteasome modulators
TW200401638A (en) 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
EP1551795A1 (en) * 2002-10-17 2005-07-13 Methylgene, Inc. Inhibitors of histone deacetylase
WO2004043374A2 (en) * 2002-11-06 2004-05-27 Dana-Farber Cancer Institute, Inc. Methods and compositions for treating cancer using proteasome inhibitors
JP2006508986A (ja) 2002-11-20 2006-03-16 エルラント ゲネ セラペウチクス エルエルシー ヒストンデアセチラーゼ阻害剤による肺細胞の治療方法
EP1599449A2 (en) * 2003-02-25 2005-11-30 TopoTarget UK Limited Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors
PE20050206A1 (es) * 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
EP1644323B1 (en) 2003-07-07 2015-03-18 Georgetown University Histone deacetylase inhibitors and methods of use thereof
WO2005012247A1 (en) 2003-07-30 2005-02-10 Hôpital Sainte-Justine Compounds and methods for the rapid quantitative analysis of proteins and polypeptides
HRP20060080A2 (en) 2003-08-26 2006-07-31 Sloan-Kettering Institute For Cancer Research Method of treating cancer with hdac inhibitors
US20050137234A1 (en) 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
CA2555812A1 (en) * 2004-02-13 2005-09-01 President And Fellows Of Harvard College 3-3-di-substituted-oxindoles as inhibitors of translation initiation
WO2006006080A2 (en) 2004-07-08 2006-01-19 Bizmedic Co., Ltd. Sodium channel agonist
CN103230394B (zh) 2004-12-03 2016-04-20 达纳-法伯癌症研究公司 治疗肿瘤性疾病的化合物及其用途
JP2008522975A (ja) 2004-12-03 2008-07-03 ネレアス ファーマシューティカルズ インコーポレイテッド ［３．２．０］複素環式化合物及びそれらのアナログを使用する方法
SG171690A1 (en) * 2005-03-22 2011-06-29 Harvard College Treatment of protein degradation disorders
DK2010168T3 (da) * 2006-02-14 2014-07-21 Harvard College Histondeacetylase-inhibitore
WO2008091349A1 (en) 2006-02-14 2008-07-31 The President And Fellows Of Harvard College Bifunctional histone deacetylase inhibitors
WO2007130429A2 (en) * 2006-05-03 2007-11-15 The President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
US8088951B2 (en) * 2006-11-30 2012-01-03 Massachusetts Institute Of Technology Epigenetic mechanisms re-establish access to long-term memory after neuronal loss

Also Published As

Publication number Publication date
US20140213620A1 (en) 2014-07-31
AU2007214458B2 (en) 2012-04-19
BRPI0707826A2 (pt) 2011-05-10
BRPI0707826B1 (pt) 2022-04-19
US20100056588A1 (en) 2010-03-04
IL193458A (en) 2016-04-21
CA2642288C (en) 2014-10-07
US9724321B2 (en) 2017-08-08
CN103739515B (zh) 2015-11-25
WO2007095584A3 (en) 2009-05-22
US9199923B2 (en) 2015-12-01
JP2009526865A (ja) 2009-07-23
ES2481413T3 (es) 2014-07-30
EP2010168B1 (en) 2014-04-16
CA2642288A1 (en) 2007-08-23
JP2013100327A (ja) 2013-05-23
US20160143874A1 (en) 2016-05-26
AU2007214458A1 (en) 2007-08-23
CN103739515A (zh) 2014-04-23
HK1126754A1 (en) 2009-09-11
EP2010168A4 (en) 2011-06-01
PL2010168T3 (pl) 2014-09-30
CN101528679A (zh) 2009-09-09
EP2010168A2 (en) 2009-01-07
US8383855B2 (en) 2013-02-26
AU2007214458C1 (en) 2012-12-06
MX2008010462A (es) 2009-04-17
US20170360740A1 (en) 2017-12-21
IL193458A0 (en) 2009-08-03
US10172821B2 (en) 2019-01-08
US20150038581A1 (en) 2015-02-05
DK2010168T3 (da) 2014-07-21
WO2007095584A2 (en) 2007-08-23

Similar Documents

Publication Publication Date Title
JP5497431B2 (ja) ヒストンデアセチラーゼおよびチューブリンデアセチラーゼ阻害剤
JP2013100327A (ja) ヒストンデアセチラーゼ阻害剤
JP5441416B2 (ja) 二官能性ヒストンデアセチラーゼインヒビター
JP5665740B2 (ja) デアセチラーゼ阻害剤およびその使用
HK1125580B (en) Bifunctional histone deacetylase inhibitors
HK1126754B (en) Histone deacetylase inhibitors
AU2012205241A1 (en) Histone deacetylase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110727

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120821

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120822

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121119

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121220

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131015

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131105

R150 Certificate of patent or registration of utility model

Ref document number: 5409015

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250